NF-kappa-B inhibitor-interacting Ras-like protein 1 (NKIRAS1)

NF-kappa-B inhibitor-interacting Ras-like protein 1 (NKIRAS1) is an atypical member of the Ras superfamily of small GTPases and acts as a potent regulator of the NF-kappa-B and Ral signaling pathways[1][5]. Unlike classical Ras proteins, NKIRAS1 lacks lipid modification motifs and appears to mainly exist in its GTP-bound form in cells[3]. It binds NF-kappa-B inhibitor proteins (IκBα and IκBβ) and suppresses their phosphorylation and proteasomal degradation, thereby inhibiting NF-kappa-B transcriptional activation and inflammatory signaling[1][3]. It also interacts with the RelA subunit of NF-kappa-B, further modulating its function[3]. NKIRAS1 is broadly expressed and its loss or downregulation—often mediated by specific microRNAs—is frequently observed in a wide spectrum of human tumors, where it correlates with poor prognosis and a pro-tumorigenic transcriptional profile (including increased KRAS/MYC/STAT3 signaling and epithelial-mesenchymal transition)[2]. Its function is context- and level-dependent, acting as a tumor suppressor but displaying complex roles in different cancers and cellular backgrounds[2][3]. Currently, no direct pharmacological modulators are in clinical use, but its expression may serve as a biomarker for tumor prognosis and could represent a future therapeutic avenue focused on restoration of its activity[2][3].

Other names

NF-kappa-B inhibitor-interacting Ras-like protein 1NKIRAS1KBRAS1Kappa B-Ras protein 1KappaB-Ras1I-kappa-B-interacting Ras-like protein 1kappaB-Ras1NFKB inhibitor interacting Ras-like protein 1kappa B-ras 1

Not applicable: no known direct drug inhibitors or modulators; action is mainly through regulation of signaling pathways